




>>>**Entry Name:** Ganciclovir, BAN, INN, USAN

**Synonym(s):** 2-Amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6*H*-purin-6-one, 9Cl. 9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine. 2'-Nor-2'-deoxyguanosine. Cytovene. DHPG. 2'-NDG. RS 21592. Biolf 62. BW B759U



**CAS Registry Number:** 82410-32-0

**Related CAS Registry Numbers(s):** 175865-61-9 175865-62-0 175865-64-2 175865-67-5

**Molecular Formula:** C<sub>9</sub>H<sub>13</sub>N<sub>5</sub>O<sub>4</sub>

**Molecular Weight:** 255.233

**Accurate Mass:** 255.096755

**Percentage Composition:** C 42.35%; H 5.13%; N 27.44%; O 25.07%

**Biological Use/Importance:** Antiviral agent; active against herpes simplex virus types 1 and 2. Administered (ivn) in treatment of cytomegalovirus

**Physical Description:** Cryst. (H<sub>2</sub>O)

**Development Status:** Launched 1988

**Melting Point:** Mp 300°

**Calculated Log P Data:** Log P -3.22 (calc)

**Hazard & Toxicity:** Exp. carcinogen. Exp. reprod. and teratogenic effects

**Sigma:** G2536

>>>**Derivative:** Monohydrate

**Melting Point:** Mp 248-249 dec.°

>>>**Derivative:** L-Valine monoester

**Synonym(s):** Valganciclovir, INN. Ganciclovir valine

**CAS Registry Number:** 175865-60-8

**Molecular Formula:** C<sub>14</sub>H<sub>22</sub>N<sub>6</sub>O<sub>5</sub>

**Molecular Weight:** 354.365

**Accurate Mass:** 354.165169

**Percentage Composition:** C 47.45%; H 6.26%; N 23.72%; O 22.57%

**Biological Use/Importance:** Stable prodrug of ganciclovir. Exhibits improved oral absorption

>>>**Derivative:** L-Valine monoester, hydrochloride

**Synonym(s):** Valganciclovir hydrochloride, USAN

**CAS Registry Number:** 175865-59-5

**Physical Description:** Cryst. (2-propanol aq.)

**Melting Point:** Mp 175° (dec.) (phase change at 142°)

#### References:

- Ashton, W.T. *et al.*, *Biochem. Biophys. Res. Commun.*, 1982, **108**, 1716, (*synth, uv, pmr, props*)
- Martin, J.C. *et al.*, *J. Med. Chem.*, 1983, **26**, 759, (*synth, uv, pmr, cmr, props*)
- Matthews, T. *et al.*, *Rev. Infect. Dis.*, S490, 1988, **10**, (*rev*)
- Faulds, D. *et al.*, *Drugs*, 1990, **39**, 597, (*rev, pharmacol*)
- Capparell, E. *et al.*, *Ganciclovir Ther. Cytomegalovirus Infect. 1991*, (ed. S.A. Spector) Dekker, 1991, 71, (*rev*)
- Alhede, B. *et al.*, *J.O.C.*, 1991, **56**, 2139-2143, (*synth, cmr*)
- Freie, H.M.P., *Med. Klin. (Munich)*, (Suppl. 1), 1992, **87**, 20, (*rev*)
- Verheyden, J.P.H., *Chron. Drug Discovery*, 1993, **3**, 299, (*ganciclovir, rev*)
- Martindale, *The Extra Pharmacopoeia*, 30th edn., Pharmaceutical Press, 1993, 546
- Eur. Pat.*, 1996, Hoffmann-LaRoche, 694 547; CA, **124**, 290266j, (*synth, pharmacol, valganciclovir*)
- Noble, S. *et al.*, *Drugs*, 1998, **56**, 115-146, (*rev*)
- Boryski, J. *et al.*, *Synthesis*, 1999, 625-628, (*synth, uv*)
- Gao, H. *et al.*, *Synthesis*, 2000, 329-351, (*rev*)